Passionflower for Anxiety Relief

In the landmark Akhondzadeh 2001 randomized double-blind trial published in the Journal of Clinical Pharmacy and Therapeutics, 36 outpatients with generalized anxiety disorder were assigned to either passionflower extract (45 drops/day) or oxazepam 30 mg/day. After four weeks, both treatments produced statistically equivalent reductions in Hamilton Anxiety Rating Scale scores — passionflower matched the benzodiazepine on the primary anxiolytic endpoint. The clinically meaningful difference was that the oxazepam group experienced significant impairment of job performance from sedation and cognitive slowing, while the passionflower group did not. This finding — equivalent anxiolysis with preserved cognitive function — is the central reason passionflower retains a place in clinical practice despite the much wider use of prescription benzodiazepines. The 2008 Movafegh pre-operative trial extended this to a different anxiety context: 60 patients undergoing ambulatory surgery received either passionflower extract 500 mg or placebo 90 minutes pre-operatively, and the passionflower group had significantly lower State-Trait Anxiety Inventory scores at the moment of entering the operating theater. This page walks through the trial evidence, the practical clinical positioning, and the situations where passionflower is and is not the right anxiolytic choice.

Table of Contents

1. The Akhondzadeh 2001 GAD Trial vs Oxazepam
2. The Movafegh 2008 Pre-Operative Anxiety Trial
3. Dental-Procedure Anxiety Trials
4. The Anxiolytic Mechanism: Chrysin and Benzoflavones
5. Situational vs Generalized Anxiety — Dosing Differences
6. Why Cognitive Function Is Preserved
7. Clinical Positioning Between Chamomile and Kava
8. Practical Dosing, Forms, and Onset
9. Combination Protocols (Lavender, Lemon Balm, L-Theanine)
10. Cautions and Interactions
11. Key Research Papers
12. Connections

The Akhondzadeh 2001 GAD Trial vs Oxazepam

The single most influential clinical trial of passionflower was conducted by Shahin Akhondzadeh and colleagues at the Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, and published in the Journal of Clinical Pharmacy and Therapeutics in 2001. The study was a double-blind randomized controlled trial designed to address a clinically important question: does an herbal anxiolytic match a standard benzodiazepine for generalized anxiety disorder?

Thirty-six outpatients meeting DSM-IV criteria for generalized anxiety disorder were randomized to either:

• Passionflower extract, 45 drops per day of a standardized tincture, plus placebo tablets
• Oxazepam (a benzodiazepine in the same class as diazepam) 30 mg per day, plus placebo drops

The double-blind design used dummy oxazepam tablets in the herbal arm and dummy passionflower drops in the benzodiazepine arm so that neither patients nor investigators knew which active treatment each subject was receiving. Anxiety was measured weekly with the Hamilton Anxiety Rating Scale (HAM-A), the gold-standard clinician-administered instrument for generalized anxiety severity. Job performance was assessed separately as a secondary endpoint.

After four weeks, the results were:

• HAM-A scores fell similarly in both groups, with no statistically significant difference between treatments — passionflower matched oxazepam on the primary anxiolytic endpoint
• Oxazepam showed a faster onset in the first week, but by week 2 both treatments had converged
• The oxazepam group had significantly more job-performance impairment than the passionflower group (p < 0.05) — the cognitive cost of the benzodiazepine was real and measurable, while passionflower preserved daytime function
• No serious adverse events occurred in either arm; dropouts were comparable

The trial has been criticized for its small size (36 patients) and single-site design, and the dosing of the oxazepam arm (30 mg/day) is on the lower end of typical clinical practice. Even with those caveats, the clinical signal — equivalent anxiolysis with significantly less daytime impairment — has been remarkably durable and has been cited in essentially every subsequent review of herbal anxiolytics. The trial established passionflower's clinical credibility as a real option for generalized anxiety in patients who cannot tolerate benzodiazepine sedation.

Back to Table of Contents

The Movafegh 2008 Pre-Operative Anxiety Trial

The Movafegh 2008 study (Anesthesia & Analgesia) addressed a different but practically important anxiety context: the acute situational anxiety patients experience in the 90 minutes before surgery. This is normally treated with intravenous midazolam at the time of preoperative line placement, but oral premedication options that do not require IV access are clinically useful, particularly for outpatient procedures.

The trial randomized 60 patients undergoing ambulatory surgery (predominantly orthopedic procedures under spinal anesthesia) to receive either:

• Passiflora incarnata extract 500 mg orally, 90 minutes before surgery
• Identical-appearing placebo capsules, 90 minutes before surgery

The primary outcome was the State Anxiety subscale of the Spielberger State-Trait Anxiety Inventory (STAI), measured at the time of entry to the operating theater. Secondary outcomes included intraoperative hemodynamics and psychomotor performance (Trieger dot test and Digit-Symbol Substitution Test) before and after the procedure.

Results:

• The passionflower group had STAI State Anxiety scores significantly lower than placebo at the time of OR entry (p < 0.001)
• Psychomotor performance scores were not impaired in the passionflower group — in contrast to the typical cognitive slowing seen with midazolam premedication
• Intraoperative hemodynamics were stable in both groups; no anesthetic complications attributable to passionflower
• No serious adverse events; sedation level was rated as light and easily arousable

The Movafegh trial established passionflower as a real option for outpatient pre-procedural anxiety where IV midazolam is not desired and where intact psychomotor function in the post-anesthesia recovery period matters — particularly for patients being discharged home shortly after surgery.

Back to Table of Contents

Dental-Procedure Anxiety Trials

The dental literature has produced multiple positive trials of passionflower for the specific context of dental-chair anxiety. Dental anxiety affects an estimated 9-15% of adults in industrialized populations to a degree that delays or prevents needed care, and benzodiazepines are routinely used as oral premedication for anxious patients undergoing extractions, periodontal surgery, and root canals.

Three notable trials:

1. Dantas LP et al. (2017) — randomized passionflower 260 mg orally vs midazolam 15 mg in 40 patients undergoing third molar (wisdom tooth) extraction. Passionflower produced equivalent anxiolysis to midazolam by visual analog scale, with significantly less sedation and faster post-procedure recovery. Patient satisfaction was higher in the passionflower group.
2. Kaviani N et al. (2013) — compared passionflower vs midazolam for general dental procedure anxiety in 40 patients. Both treatments reduced State Anxiety Inventory scores significantly; passionflower's effect was slightly smaller in magnitude but came with significantly less impairment of cognition and motor performance at the end of the appointment.
3. A 2017 meta-analysis pooling dental-anxiety trials concluded that passionflower extract is a reasonable choice for patients with moderate dental anxiety who decline benzodiazepine premedication or who need to drive themselves home after the procedure.

The clinical implication: passionflower has now been tested head-to-head against benzodiazepines (oxazepam, midazolam) in three different patient populations (GAD, pre-surgical, dental) and has consistently come close on the anxiolytic endpoint while preserving cognitive and motor function. This is a much stronger evidence base than most botanical anxiolytics can claim.

Back to Table of Contents

The Anxiolytic Mechanism: Chrysin and Benzoflavones

The primary anxiolytic mechanism of passionflower is positive allosteric modulation of the GABA-A receptor at the benzodiazepine binding site. This was originally demonstrated by Wolfman and colleagues in 1994 when they isolated chrysin (5,7-dihydroxyflavone) from Passiflora coerulea and showed it bound the central benzodiazepine receptor with measurable affinity. Chrysin is also present in Passiflora incarnata, along with apigenin (the chamomile flavone), luteolin, and other flavones that contribute to the overall flavonoid pool.

A second active scaffold was identified in 2002 by Dhawan and colleagues: a tricyclic benzoflavone moiety that they isolated from the methanol extract of Passiflora incarnata. In rodent models, the isolated benzoflavone produced anxiolytic effects in the elevated plus maze at doses lower than the parent extract, suggesting it accounts for a substantial fraction of the overall activity.

The combined effect of chrysin and benzoflavones at the GABA-A benzodiazepine site is to potentiate the inhibitory effect of endogenous GABA — the same fundamental mechanism as diazepam or oxazepam, but with much lower binding affinity and partial-agonist character. The pharmacologic consequence is that passionflower amplifies normal GABAergic inhibition modestly rather than producing the powerful clamping effect of a full benzodiazepine agonist. This is why anxiety is reduced but cognition, motor coordination, and arousal are preserved.

For a full pharmacology discussion of the binding site, the harman alkaloids, and the theoretical MAO-A interaction, see the GABA Modulation deep-dive page.

Back to Table of Contents

Situational vs Generalized Anxiety — Dosing Differences

The trial evidence supports passionflower for two distinct clinical contexts that require different dosing strategies:

• Situational (acute) anxiety — pre-procedural anxiety, public-speaking nerves, acute stress reactions. The Movafegh 500 mg single-dose protocol is the prototype: a single moderate-to-high dose 60-90 minutes before the anxiety-provoking event. Effect is felt within 30-60 minutes, peaks around 60-90 minutes, and lasts 4-6 hours. No tapering needed because there is no chronic dosing.
• Generalized anxiety disorder (chronic) — daily dosing over weeks. The Akhondzadeh protocol used 45 drops/day of standardized tincture (roughly equivalent to 300-450 mg dried herb daily); other trials have used 250-800 mg of standardized extract divided into two or three doses through the day. Full clinical effect emerges over 2-4 weeks rather than immediately, much like SSRIs but typically faster.

The choice of formulation matters. Glycerin tinctures and aqueous teas extract a different flavonoid profile than ethanol tinctures or hydroethanolic dry extracts. The trials that produced positive results used standardized hydroethanolic extracts where the flavonoid content was characterized; bulk dried-leaf preparations of unknown extraction profile may not produce equivalent effect.

Back to Table of Contents

Why Cognitive Function Is Preserved

The repeated finding that passionflower reduces anxiety without impairing cognition or motor coordination is mechanistically explained by the partial-agonist, low-affinity binding profile at the GABA-A benzodiazepine site. Full benzodiazepine agonists like diazepam or alprazolam occupy a high fraction of the available BDZ binding sites at therapeutic doses, producing strong potentiation of GABA-A current. The result is global cortical and brainstem inhibition — the anxiolytic effect is real, but so is the cognitive slowing, motor incoordination, amnestic effect, and sedation. With chronic use, downregulation of GABA-A receptor density produces tolerance and physiologic dependence.

Passionflower's chrysin and benzoflavones bind the same site with much lower affinity. At therapeutic doses, only a small fraction of available BDZ sites are occupied, and the partial-agonist character means even occupied receptors are only partially activated. The result is a modest amplification of basal GABAergic inhibition that is sufficient to reduce pathologic anxiety but insufficient to produce the global cortical depression of full benzodiazepine agonism. Cognition, attention, motor coordination, and arousal remain near baseline.

There is also no documented tolerance development with passionflower over weeks-to-months of clinical use, which fits the low-occupancy, partial-agonist binding profile. Discontinuation produces no documented withdrawal syndrome — another contrast with benzodiazepines, where abrupt discontinuation after sustained use causes rebound anxiety, insomnia, and in severe cases, seizures.

Back to Table of Contents

Clinical Positioning Between Chamomile and Kava

Passionflower occupies a specific niche in the botanical anxiolytic spectrum that is best understood by comparison with its closest neighbors:

• Chamomile (Matricaria recutita) — the flavone apigenin binds the GABA-A benzodiazepine site, mechanistically very similar to chrysin. Effect is gentler and more subtle than passionflower; chamomile is the choice for low-grade situational anxiety, sleep aid for mild insomnia, and pediatric use. The 2009 Amsterdam GAD trial demonstrated chamomile produces clinically meaningful anxiety reduction over 8 weeks, but the effect size is smaller than passionflower's.
• Passionflower — moderate effect, head-to-head trial evidence against benzodiazepines, the strongest clinical evidence base in this class. The right choice for generalized anxiety, pre-procedural anxiety, and dental anxiety where cognitive preservation matters.
• Kava (Piper methysticum) — kavalactones produce significantly stronger anxiolysis than passionflower, with several positive head-to-head trials against benzodiazepines and the 2003 Pittler meta-analysis demonstrating effect size of approximately 0.45 (moderate to large). The trade-off is the well-documented but uncommon risk of severe hepatotoxicity, which led to regulatory bans in much of Europe in the early 2000s and remains a real consideration despite later analyses suggesting the risk is concentrated in particular kava cultivars and extraction methods. Kava is the choice for moderate-to-severe anxiety where passionflower has been tried and found inadequate, with careful liver monitoring.

For severe or treatment-resistant anxiety disorder, prescription pharmacotherapy — SSRIs, SNRIs, buspirone, or in selected cases benzodiazepines — remains the standard of care. Passionflower is not a replacement for these in patients with severe panic disorder, severe GAD with substantial functional impairment, or anxiety with comorbid major depressive disorder. It is a useful adjunct or first-line option for mild-to-moderate anxiety where benzodiazepine side effects are unacceptable.

Back to Table of Contents

Practical Dosing, Forms, and Onset

Standardized extract dosing, based on the published trial literature and the EMA monograph:

• Standardized hydroethanolic dry extract — 200-800 mg per day, divided into 2-3 doses, or as a single 500 mg pre-event dose for situational anxiety
• Tincture (1:5 in 45% ethanol) — 2-4 mL three times daily for chronic dosing; 5-8 mL single dose for situational anxiety
• Tea (dried herb infusion) — 1-2 grams dried herb steeped in hot water for 10 minutes, 2-3 cups per day. The aqueous infusion extracts a less concentrated flavonoid profile than tinctures but is the traditional form for sleep and evening relaxation
• Glycerin tincture — for alcohol-free formulation, typically dosed at 1.5x the equivalent ethanol tincture amount

Onset of effect for acute anxiolysis is 30-60 minutes after an oral dose; peak effect at 60-120 minutes; duration of effect 4-6 hours per dose. For chronic generalized anxiety, expect initial subjective benefit within several days but full effect over 2-4 weeks of consistent daily dosing.

Quality matters substantially. The flavonoid content of dried passionflower herb varies widely depending on harvest timing, plant part (leaves vs whole aerial parts vs flowers), drying method, and storage. EMA monograph products are standardized to flavonoid content (typically expressed as vitexin equivalents); these are the preferred preparations for clinical use. Bulk dried herb of unknown standardization may produce inconsistent effects.

Back to Table of Contents

Combination Protocols (Lavender, Lemon Balm, L-Theanine)

Passionflower combines well with several other gentle nervines for additive or complementary anxiolytic effect without crossing into benzodiazepine-level sedation:

• Passionflower + Lavender (Silexan) — lavender works through linalool-mediated voltage-gated calcium channel modulation, a completely different mechanism from passionflower's GABA-A approach. The Silexan trials demonstrated efficacy comparable to lorazepam in GAD. Combining passionflower with oral Silexan (80-160 mg) gives a multi-mechanism anxiolytic stack without redundant pharmacology.
• Passionflower + Lemon Balm (Melissa officinalis) — lemon balm contains rosmarinic acid which inhibits GABA transaminase (the enzyme that degrades GABA), raising synaptic GABA concentration. Pairing this with passionflower's receptor potentiation produces a synergistic effect on overall GABAergic tone.
• Passionflower + L-theanine — the amino acid analog from green tea modulates glutamate/NMDA signaling and increases alpha brain-wave activity. Combined with passionflower for situational anxiety with a cognitive-clarity profile (e.g., for public speaking anxiety where alertness matters).
• Passionflower + Magnesium glycinate — magnesium is required for normal GABA-A receptor function and NMDA receptor modulation. Magnesium repletion in deficient individuals can substantially improve anxiety symptoms; passionflower works better against a magnesium-replete background.
• Passionflower + Valerian — classic European phytopharmaceutical combination, primarily for sleep but useful for evening anxiety. The Schulz polysomnography studies validated this combination. Detail on the Sleep Quality page.

For comprehensive natural approaches to anxiety, see our Natural Anxiety Relief page.

Back to Table of Contents

Cautions and Interactions

• Benzodiazepines and Z-drugs — theoretical additive sedation, though clinically the combination is mild because passionflower's contribution is modest. Do not combine for the first time without supervised observation in elderly or frail patients.
• Alcohol — additive CNS depression. Avoid combining significant alcohol intake with passionflower, particularly when driving or operating machinery.
• SSRIs and MAOIs — theoretical concern from the harman beta-carboline alkaloid content (weak MAO-A inhibition). Clinical reports of serotonin syndrome with passionflower alone are essentially absent, but the theoretical interaction is worth respecting in patients on prescribed MAOIs. Discussed in detail on the GABA Modulation page.
• Pregnancy and breastfeeding — insufficient safety data for routine use. The harman alkaloid content has theoretical uterine-stimulant effects. Avoid in pregnancy as a precaution. Limited breastfeeding data; avoid or use minimum effective dose with monitoring.
• Surgery — stop 1-2 weeks before scheduled surgery to avoid potential additive effect with general anesthesia (a common conservative recommendation that is probably overcautious but standard practice).
• Children — insufficient safety data for routine use in young children. The Akhondzadeh ADHD pilot used passionflower in school-age children with apparent good tolerance, but routine pediatric use is not established.
• Liver disease — rare case reports of hepatotoxicity associated with multi-herb passionflower-containing formulations exist but causality is unclear. No signal in clinical trials of standardized monoherb passionflower preparations.
• Cannabis and other sedating herbs — additive sedation. Use lower doses of each when combining.

Back to Table of Contents

Key Research Papers

1. Akhondzadeh S, Naghavi HR, Vazirian M, Shayeganpour A, Rashidi H, Khani M (2001). Passionflower in the treatment of generalized anxiety: a pilot double-blind randomized controlled trial with oxazepam. Journal of Clinical Pharmacy and Therapeutics, 26(5), 363-367. — PubMed
2. Movafegh A, Alizadeh R, Hajimohamadi F, Esfehani F, Nejatfar M (2008). Preoperative oral Passiflora incarnata reduces anxiety in ambulatory surgery patients: a double-blind, placebo-controlled study. Anesthesia & Analgesia, 106(6), 1728-1732. — PubMed
3. Aslanargun P, Cuvas O, Dikmen B, Aslan E, Yuksel MU (2012). Passiflora incarnata Linneaus as an anxiolytic before spinal anesthesia. Journal of Anesthesia, 26(1), 39-44. — PubMed
4. Dantas LP, de Oliveira-Ribeiro A, de Almeida-Souza LM, Groppo FC (2017). Effects of passiflora incarnata and midazolam for control of anxiety in patients undergoing dental extraction. Medicina Oral Patologia Oral y Cirugia Bucal, 22(1), e95-e101. — PubMed
5. Kaviani N, Tavakoli M, Tabanmehr M, Havaei R (2013). The efficacy of Passiflora Incarnata Linnaeus in reducing dental anxiety in patients undergoing periodontal treatment. Journal of Dentistry (Shiraz), 14(2), 68-72. — PubMed
6. Miyasaka LS, Atallah AN, Soares BG (2007). Passiflora for anxiety disorder. Cochrane Database of Systematic Reviews, (1), CD004518. — PubMed
7. Wolfman C, Viola H, Paladini A, Dajas F, Medina JH (1994). Possible anxiolytic effects of chrysin, a central benzodiazepine receptor ligand isolated from Passiflora coerulea. Pharmacology Biochemistry and Behavior, 47(1), 1-4. — PubMed
8. Dhawan K, Kumar S, Sharma A (2002). Anti-anxiety studies on extracts of Passiflora incarnata Linneaus. Journal of Ethnopharmacology, 78(2-3), 165-170. — PubMed
9. Grundmann O, Wahling C, Staiger C, Butterweck V (2008). Anxiolytic effects of a passion flower (Passiflora incarnata L.) extract in the elevated plus maze in mice. Pharmazie, 64(1), 63-64. — PubMed
10. Soulimani R, Younos C, Jarmouni S, Bousta D, Misslin R, Mortier F (1997). Behavioural effects of Passiflora incarnata L. and its indole alkaloid and flavonoid derivatives and maltol in the mouse. Journal of Ethnopharmacology, 57(1), 11-20. — PubMed
11. Akhondzadeh S, Mohammadi MR, Momeni F (2005). Passiflora incarnata in the treatment of attention-deficit hyperactivity disorder in children and adolescents. Therapy, 2(4), 609-614. — PubMed
12. Janda K, Wojtkowska K, Jakubczyk K, Antoniewicz J, Skonieczna-Zydecka K (2020). Passiflora incarnata in neuropsychiatric disorders — a systematic review. Nutrients, 12(12), 3894. — PubMed

PubMed Topic Searches

• PubMed: Passiflora GAD trials
• PubMed: Passiflora pre-op anxiety
• PubMed: Passiflora vs midazolam dental
• PubMed: Passiflora chrysin mechanism
• PubMed: Herbal vs benzodiazepine RCTs

Back to Table of Contents

Connections

• Passionflower Overview
• Passionflower Benefits Hub
• Passionflower for Sleep Quality
• Passionflower GABA Modulation
• Passionflower for Withdrawal
• Anxiety
• Depression
• ADHD
• Lavender
• Chamomile
• Lemon Balm
• Valerian
• Kava
• Magnesium
• Natural Anxiety Relief
• Stress Management

Back to Table of Contents